08 Sep 2022 Governance
Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II
On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement:
“We are extremely saddened to hear the news of the death of Her Majesty Queen Elizabeth II. 
Together with the nation and people around the world, we remember a true leader who gave her life to duty. The Queen’s dedication, diligence and integrity were an inspiration to all and we are thankful for an inspiring monarch, who gave her life in service of her country and the Commonwealth.
The Queen’s support for the charity sector has enabled charities in the UK to thrive during her reign and will have a lasting impact for those whom the charities support.
We share our condolences with the entire Royal Family and especially the Queen’s children and grandchildren. Our thoughts are with them at this very difficult time.”
Related posts
4 April 2022
Leukaemia UK launches search for five new talented Trustees
We are looking for a talented and diverse set of Trustees to join our Board, and help guide the charity as we embark on an ambitious new strategy to accelerate progress in leukaemia research to stop leukaemia devastating lives.
8 September 2022
Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II
On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement: “We are extremely saddened to hear the news of the death of…
10 November 2021
An urgent call from One Cancer Voice group of cancer charities for the Comprehensive Spending Review to deliver Government commitments to improve cancer survival & care
Leukaemia UK has joined with 50 other cancer charities in writing to the Prime Minister, Chancellor of the Exchequer and Secretary of State for Health and Social Care. We are calling on the Government to urgently deliver on commitments to improve cancer survival and care in the forthcoming Spending Review.
21 May 2020
A new clinical trial announced
A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.